

DAFTAR PUSTAKA

- American Cancer Society., (2016, September 13). Breast Cancer. Dipetik Januari 4, 2017, dari American Cancer Society: <http://www.cancer.org/acs/groups/cid/documents/webcontent/003090-pdf.pdf>
- Arslan N, Serdar M, Deveci S, Ozturk B, Narrin Y, Ilgan S, Ozturk E, Ozguren MA. Use of CA 15-3, CEA and Prolactin For The Primary Diagnosis of Breast Cancer and Correlation with The prognostic Factors at the time of initial diagnosis. Abstract. NCBI. Ann Nucl Med. 2000:Oct; 14(5): 395-9
- Aysola, K., Desai A., Welch, C., Xu, J., Qin, Y., Reddy, V., Matthews, R., Owens, C., Okoli, J., Beech D J., Piyathilake, C. J., Reddy, S. P., Rao, V. N., Triple Negative Breast Cancer-An Overview. Hereditary Genetics.2013
- Bland KI, Copeland EM. Editors. The Breast Comprehensive Management of Benign and Malignant Diseases. Philadelphia. WB Saunders company. 2009.
- Box, B.A., and Russel, C.A. 2009. Breast Cancer; in Manual of Clinical Oncology, 6th ed. Los Angeles: Lipincott Williams & Wilkins. p. 238-263.
- Compton, C. C., Byrd, R. D., Fritz, G. A., Greene, F. L., Trotti, A., AJCC Cancer Staging Atlas Second Edition. Springer.2012. 221-240
- Compton, Carolyn C., Byrd, David R., Garcia-Aguilar, Julio., Kurtzman, Scott H., Olawaiye, Alexander., and Washington, Mary Kay. 2012. AJCC Cancer Staging Atlas Second Edition. Springer Science+Business Media, LLC , 32 : 419-440.
- Dai, X., Li, T., Bai, Z., Yang, Y., Liu, X., Zhan, J., Shi, B., Breast cancer intrinsic subtype classification, clinical use and future trends. Am J Cancer. Chongqing, China. 2015. 5(10);2929-2943
- Desen, W. W., Buku Ajar Onkologi Klinis, edisi 2. Fakultas Kedokteran Universitas Indonesia. Jakarta. 2008. h; 365-383.
- Dorit Laessig, Dorothea Nagel, Volker Heinemann, Importance of CEA and CA15-3 during Disease Progression in Metastatic Breast Cancer Patients, Anticancer Research 27: 1963-1968 (2007).
- Geng, B., Liang, M. M., Ye, X. B., Zhao, W. Y., Association of CA 15-3 and CEA with clinicopathological parameters in patients with metastatic breast cancer.

Molecular and Clinical Oncology. China. 2014. Diakses dari <https://www.spandidos-publications.com/10.3892/mco.2014.419>

Ghoncheh, M., MahdaviFar, N., Darvishi, E., Salehiniya, H., Epidemiology, Incidence and Mortality of Breast Cancer in Asia. *Asian Pac J Cancer Prev.* 2016. 17: 47-52.

Globocan., International Agency for Research on Cancer (IARC). Estimated Cancer Incidence Mortality and Prevalence Worldwide, Lyon 2012. Diakses dari <http://globocan.iarc.fr/Default.aspx>

Goldhirsch, A., Winer, E. P., Coates, A. S., Gelber, R. D., Piccart-Gebhart, M., Thürlimann, B., Sen, H.J., Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. *Annals of Oncology.*2013. 24: 2206–2223

Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, et al Editors. The AJCC Cancer Staging Manual. New York. 7 th Edition. 2010.

Hashmi, A. A., Aijaz, S., Khan, S. M., Mahboob, R., Irfan, M., Zafar, N. I., Nisar, M., Siddiqui, M., Edhi, M. M., Faridi, N., Khan, A., Prognostic parameters of luminal A and luminal B intrinsic breast cancer subtypes of Pakistani patients. *World Journal of Surgical Oncology.*Kandahar. Afghanistan.2018.16:1

IARC, 2016. Globocan 2012: Estimated Cancer Incidence, Mortality And Prevalence Worldwide In 2012. <Http://www-Dep.Iarc.Fr/>, Globocan (August), 2012-2013. Retrieved From www-dep.iarc.fr

Jennifer J Rahn, Jing Zhang, Qiang Shen, Molecular Cancer Research: MUC1 Initiates Src-CrkL-Rac1/Cdc42-Mediated Actin Cytoskeletal Protrusive Motility after Ligating Intercellular Adhesion Molecule-1, 2008, 6: 555-567.

Kemenkes, 2015. Situasi Penyakit Kanker : 4 Februari-Hari Kanker Sedunia.<http://www.depkes.go.id/resources/download/pusdatin/infodatin/infodatin-kanker.pdf>. Diunduh pada 13 Agustus 2017.

Keyhani M, Nasizadeh S, Dehghannejad A; Serum CA 15-3 Measurement in Breast Cancer Patients Before and After Mastectomy, *Archives of Iranian Medicine*, Volume 8, Number 4, 2005;263-66.

Kumar, V., Cotran, R. S., & Robbins, S. L. Payudara. Dalam V. Kumar, R. S. Cotran, & S. L. Robbins, *Buku Ajar Patologi Edisi 7. EGC.* Jakarta. 2012. Vol. 2. Hal 759-800

Li, L. T., Jiang, G., Chen, Q., dan Zheng, J. N., Ki67 is a promising molecular target in the diagnosis of cancer.2014. <https://www.spandidos-publications.com/10.3892/mmr.2014.2914>. Diakses: 5 Mei 2018

- Manuaba, T.W. 2010. Panduan Penatalaksanaan Kanker Payudara. Panduan Penatalaksanaan Kanker Solid Peraboi 2010. Jakarta: Sagung Seto. h. 17-48.
- McPherson, K., Steel, C.M. and Dixon, J.M. 2000. ABC of Breast Diseases, Breast Cancer-Epidemiology, Risk Factors, and Genetics. *British Medical Journal*. 321: 624-628.
- Phipps, A. I., Li, C. I., Breast Cancer Biology and Clinical Characteristics Breast Cancer Epidemiology. Springer Science and Business Media, LLC 2010.
- Rakha,E.A, Reis-Filho,J.S.,Baehner, F.,Dabbs, D.J., Decker, T., Eusebi, V., and Ellis, I.O.2010. Breast Cancer Prognostic Classification in the Molecular Era : The Role of Histological Grade. *Breast Cancer Research : BCR*, 12(4), 207. <https://doi.org/10.1186/bcr2607>
- Soni, A., Ren, Z., Hameed, O., Chanda, D., Morgan, C. J., Siegal, G. P., Wei Shi. Breast Cancer Subtypes Predispose the Site of Distant Metastases.*American Journal Clinical Pathology*.2015. 143;471-478
- Sorlie. (2007). Molecular classification of breast tumor: toward improved diagnostic and treatment. 91-114.
- Tampellini M, Berruti A, Gerbino A, et al : Relationship between CA 15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease.*British Journal of Cancer* 1997: 75 (5), 698-702.
- Yersal, O., Barutca, S., Biological Subtypes of Breast Cancer: Prognostic and Therapeutic Implications. *World JournalClinical Oncology*. .2014. 5(3);412-24
- Yulianto, R. Korelasi Kadar Her-2 Serum dengan Status Her-2 Jaringan Pada Penderita Kanker Payudara Stadium Lanjut Lokal dan Stadium Metastasis di Makassar, 2013.
- Zaha, D. C., Significance of Immunohistochemistry in Breast Cancer. *World Journal Clinical Oncology*.2014. 5(3); 382-92
- Zhang, M. H., Man, H. T., Zhao, X. D., Dong, N., Ma, S. L., Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials. *Shenyang Agricultural University*.Shenyang.China.2013. 2;41-52
- Al Tamimi, D.M., Shawarby, M.A., Ahmed, A., Hassan, A.K. and AlOdaini, A.A., 2010. Protein expression profile and prevalence pattern of the molecular classes of breast cancer-a Saudi population based study. *BMC cancer*, 10(1), pp.1-13.

- Caldarella, A., Buzzoni, C., Crocetti, E., Bianchi, S., Vezzosi, V., Apicella, P., Biancalani, M., Giannini, A., Urso, C., Zolfanelli, F. and Paci, E., 2013. Invasive breast cancer: a significant correlation between histological types and molecular subgroups. *Journal of cancer research and clinical oncology*, 139(4), pp.617-623.
- Elesawy, B.H., Shawky, A.E.A. and Arafa, M., 2014. Immunohistochemistry-based subtyping of breast carcinoma in Egyptian women: a clinicopathologic study on 125 patients. *Annals of Diagnostic Pathology*, 18(1), pp.21-26.
- Hashmi, A.A., Aijaz, S., Khan, S.M., Mahboob, R., Irfan, M., Zafar, N.I., Nisar, M., Siddiqui, M., Edhi, M.M., Faridi, N. and Khan, A., 2018. Prognostic parameters of luminal A and luminal B intrinsic breast cancer subtypes of Pakistani patients. *World journal of surgical oncology*, 16(1), pp.1-6.
- Hutajulu, S.H., Prabandari, Y.S., Bintoro, B.S., Wiranata, J.A., Widiastuti, M., Suryani, N.D., Saptari, R.G., Taroeno-Hariadi, K.W., Kurnianda, J., Purwanto, I. and Hardianti, M.S., 2022. Delays in the presentation and diagnosis of women with breast cancer in Yogyakarta, Indonesia: A retrospective observational study. *PloS one*, 17(1), p.e0262468.
- Kadivar, M., Mafi, N., Joulaee, A., Shamsheiri, A. and Hosseini, N., 2012. Breast cancer molecular subtypes and associations with clinicopathological characteristics in Iranian women, 2002-2011. *Asian Pacific Journal of Cancer Prevention*, 13(5), pp.1881-1886.
- Kohler, B.A., Sherman, R.L., Howlader, N., Jemal, A., Ryerson, A.B., Henry, K.A., Boscoe, F.P., Cronin, K.A., Lake, A., Noone, A.M. and Henley, S.J., 2015. Annual report to the nation on the status of cancer, 1975-2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. *Journal of the National Cancer Institute*, 107(6), p.djv048.
- Kong, X., Liu, Z., Cheng, R., Sun, L., Huang, S., Fang, Y. and Wang, J., 2020. Variation in breast cancer subtype incidence and distribution by race/ethnicity in the United States from 2010 to 2015. *JAMA network open*, 3(10), pp.e2020303-e2020303.
- Miron, L., Marinca, A., Marinca, M. and Miron, I., 2008. Triple-negative breast cancer-towards a new entity. *Revista Medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi*, 112(1), pp.51-58.
- Rahmawati, Y., Setyawati, Y., Widodo, I., Ghozali, A. and Purnomosari, D., 2018. Molecular subtypes of Indonesian breast carcinomas-lack of association with patient age and tumor size. *Asian Pacific journal of cancer prevention: APJCP*, 19(1), p.161.

- Salhia, B., Tapia, C., Ishak, E.A., Gaber, S., Berghuis, B., Hussain, K.H., DuQuette, R.A., Resau, J. and Carpten, J., 2011. Molecular subtype analysis determines the association of advanced breast cancer in Egypt with favorable biology. *BMC women's health*, 11(1), pp.1-9.
- Shibuta, K., Ueo, H., Furusawa, H., Komaki, K., Rai, Y., Sagara, Y., Kamada, Y. and Tamaki, N., 2011. The relevance of intrinsic subtype to clinicopathological features and prognosis in 4,266 Japanese women with breast cancer. *Breast Cancer*, 18(4), pp.292-298.
- Soliman, N.A. and Yussif, S.M., 2016. Ki-67 as a prognostic marker according to breast cancer molecular subtype. *Cancer biology & medicine*, 13(4), p.496.
- Widodo, I., Dwianingsih, E.K., Anwar, S.L., Triningsih, F.E., Utoro, T. and Aryandono, T., 2017. Prognostic value of clinicopathological factors for Indonesian breast carcinomas of different molecular subtypes. *Asian Pacific Journal of Cancer Prevention: APJCP*, 18(5), p.1251.
- Widodo, I., Dwianingsih, E.K., Triningsih, E., Utoro, T. and Soeripto, S., 2014. Clinicopathological features of Indonesian breast cancers with different molecular subtypes. *Asian Pacific Journal of Cancer Prevention*, 15(15), pp.6109-6113.
- Zhu, X., Ying, J., Wang, F., Wang, J. and Yang, H., 2014. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status in invasive breast cancer: a 3,198 cases study at National Cancer Center, China. *Breast cancer research and treatment*, 147(3), pp.551-555.

Lampiran 1. Hasil Analisis Data

NEW FILE.

DATASET NAME DataSet1 WINDOW=FRONT.

FREQUENCIES VARIABLES=Umur T Grade Subtipe
/ORDER=ANALYSIS.

Frequencies

Notes

Output Created		21-DEC-2022 23:20:25
Comments		
Input	Active Dataset	DataSet1
	Filter	<none>
	Weight	<none>
	Split File	<none>
	N of Rows in Working Data File	784
Missing Value Handling	Definition of Missing	User-defined missing values are treated as missing.
	Cases Used	Statistics are based on all cases with valid data.
Syntax		FREQUENCIES VARIABLES=Umur T Grade Subtipe /ORDER=ANALYSIS.
Resources	Processor Time	00:00:00.01
	Elapsed Time	00:00:00.00

[DataSet1]

Statistics

		Umur	Ukuran Tumor	Grade	Subtipe
N	Valid	784	784	784	784
	Missing	0	0	0	0

Frequency Table

		Umur			Cumulative Percent
		Frequency	Percent	Valid Percent	
Valid	2	1	.1	.1	.1
	3	35	4.5	4.5	4.6
	4	175	22.3	22.3	26.9
	5	273	34.8	34.8	61.7
	6	233	29.7	29.7	91.5
	7	57	7.3	7.3	98.7
	8	8	1.0	1.0	99.7
	9	2	.3	.3	100.0
	Total	784	100.0	100.0	

		Ukuran Tumor			Cumulative Percent
		Frequency	Percent	Valid Percent	
Valid	1	2	.3	.3	.3
	2	47	6.0	6.0	6.3
	3a	117	14.9	14.9	21.2
	3b	50	6.4	6.4	27.6
	4a	56	7.1	7.1	34.7
	4b	222	28.3	28.3	63.0
	4c	290	37.0	37.0	100.0
	Total	784	100.0	100.0	

		Grade			Cumulative Percent
		Frequency	Percent	Valid Percent	
Valid	Low	90	11.5	11.5	11.5
	Moderate	518	66.1	66.1	77.6
	High	176	22.4	22.4	100.0
	Total	784	100.0	100.0	

		Subtipe			
		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	A Luminal	268	34.2	34.2	34.2
	B Luminal	94	12.0	12.0	46.2
	Her-2	219	27.9	27.9	74.1
	Basal Like/Triple Negatif	203	25.9	25.9	100.0
	Total	784	100.0	100.0	

NPAR TESTS

/K-W=T BY Subtipe(1 4)
/MISSING ANALYSIS.

NPar Tests

		Notes
Output Created		21-DEC-2022 23:23:13
Comments		
Input	Active Dataset	DataSet1
	Filter	<none>
	Weight	<none>
	Split File	<none>
	N of Rows in Working Data File	784
Missing Value Handling	Definition of Missing	User-defined missing values are treated as missing.
	Cases Used	Statistics for each test are based on all cases with valid data for the variable(s) used in that test.
Syntax		NPAR TESTS /K-W=T BY Subtipe(1 4) /MISSING ANALYSIS.
Resources	Processor Time	00:00:00.01
	Elapsed Time	00:00:00.00
	Number of Cases Allowed ^a	449389

a. Based on availability of workspace memory.

Kruskal-Wallis Test

Ranks

	Subtipe	N	Mean Rank
Ukuran Tumor	A Luminal	268	392.99
	B Luminal	94	363.32
	Her-2	219	420.93
	Basal Like/Triple Negatif	203	374.70
	Total	784	

Test Statistics^{a,b}

Ukuran Tumor	
Kruskal-Wallis H	6.793
df	3
Asymp. Sig.	.079

a. Kruskal Wallis Test

b. Grouping Variable: Subtipe

NPAR TESTS

/K-W=Grade BY Subtipe(1 4)

/MISSING ANALYSIS.

NPar Tests

Notes

Output Created	21-DEC-2022 23:24:25	
Comments		
Input	Active Dataset	DataSet1
	Filter	<none>
	Weight	<none>
	Split File	<none>
	N of Rows in Working Data File	784
Missing Value Handling	Definition of Missing	User-defined missing values are treated as missing.

Cases Used		Statistics for each test are based on all cases with valid data for the variable(s) used in that test.
Syntax		NPAR TESTS /K-W=Grade BY Subtipe(1 4) /MISSING ANALYSIS.
Resources	Processor Time	00:00:00.01
	Elapsed Time	00:00:00.00
	Number of Cases Allowed ^a	449389

a. Based on availability of workspace memory.

Kruskal-Wallis Test

Ranks

	Subtipe	N	Mean Rank
Grade	A Luminal	268	375.83
	B Luminal	94	347.61
	Her-2	219	419.76
	Basal Like/Triple Negatif	203	405.88
	Total	784	

Test Statistics^{a,b}

	Grade
Kruskal-Wallis H	12.921
df	3
Asymp. Sig.	.005

a. Kruskal Wallis Test

b. Grouping Variable: Subtipe

NPAR TESTS

/K-W=T BY Grade(1 3)

/MISSING ANALYSIS.

NPar Tests

Notes

Output Created	21-DEC-2022 23:25:13	
Comments		
Input	Active Dataset	DataSet1
	Filter	<none>
	Weight	<none>
	Split File	<none>
	N of Rows in Working Data File	784
Missing Value Handling	Definition of Missing	User-defined missing values are treated as missing.
	Cases Used	Statistics for each test are based on all cases with valid data for the variable(s) used in that test.
Syntax	NPAR TESTS /K-W=T BY Grade(1 3) /MISSING ANALYSIS.	
Resources	Processor Time	00:00:00.00
	Elapsed Time	00:00:00.00
	Number of Cases Allowed ^a	449389

a. Based on availability of workspace memory.

Kruskal-Wallis Test

Ranks

	Grade	N	Mean Rank
Ukuran Tumor	Low	90	295.88
	Moderate	518	387.78
	High	176	455.79
	Total	784	

Test Statistics^{a,b}

Ukuran Tumor	
Kruskal-Wallis H	32.901
df	2
Asymp. Sig.	.000

a. Kruskal Wallis Test

b. Grouping Variable: Grade

CROSSTABS

/TABLES=T BY Subtipe
 /FORMAT=AVALUE TABLES
 /CELLS=COUNT
 /COUNT ROUND CELL.

Crosstabs

Notes

Output Created	21-DEC-2022 23:59:08	
Comments		
Input	Active Dataset	DataSet1
	Filter	<none>
	Weight	<none>
	Split File	<none>
	N of Rows in Working Data File	784
Missing Value Handling	Definition of Missing	User-defined missing values are treated as missing.
	Cases Used	Statistics for each table are based on all the cases with valid data in the specified range(s) for all variables in each table.

Syntax	CROSSTABS /TABLES=T BY Subtipe /FORMAT=AVALUE TABLES /CELLS=COUNT /COUNT ROUND CELL.	
Resources	Processor Time	00:00:00.01
	Elapsed Time	00:00:00.00
	Dimensions Requested	2
	Cells Available	524245

Case Processing Summary

	Valid		Cases Missing		Total	
	N	Percent	N	Percent	N	Percent
Ukuran Tumor * Subtipe	784	100.0%	0	0.0%	784	100.0%

Ukuran Tumor * Subtipe Crosstabulation

Count		Subtipe				Total
		A Luminal	B Luminal	Her-2	Basal Like/Triple Negatif	
Ukuran Tumor	1	0	0	0	2	2
	2	21	6	10	10	47
	3a	39	20	24	34	117
	3b	16	7	14	13	50
	4a	18	6	16	16	56
	4b	71	24	64	63	222
	4c	103	31	91	65	290
Total		268	94	219	203	784

CROSSTABS
/TABLES=Grade BY Subtipe
/FORMAT=AVALUE TABLES
/CELLS=COUNT
/COUNT ROUND CELL.

Crosstabs

Notes

Output Created		22-DEC-2022 00:10:08
Comments		
Input	Active Dataset	DataSet1
	Filter	<none>
	Weight	<none>
	Split File	<none>
	N of Rows in Working Data File	784
Missing Value Handling	Definition of Missing	User-defined missing values are treated as missing.
	Cases Used	Statistics for each table are based on all the cases with valid data in the specified range(s) for all variables in each table.
Syntax	CROSSTABS /TABLES=Grade BY Subtipe /FORMAT=AVALUE TABLES /CELLS=COUNT /COUNT ROUND CELL.	
Resources	Processor Time	00:00:00.01
	Elapsed Time	00:00:00.00
	Dimensions Requested	2
	Cells Available	524245

Case Processing Summary

	Valid		Cases Missing		Total	
	N	Percent	N	Percent	N	Percent
Grade * Subtipe	784	100.0%	0	0.0%	784	100.0%

Grade * Subtype Crosstabulation

Count

		Subtype				Total
		A Luminal	B Luminal	Her-2	Basal Like/Triple Negatif	
Grade	Low	35	12	27	16	90
	Moderate	182	72	124	140	518
	High	47	10	68	51	176
Total		268	94	219	203	784

CROSSTABS

```

/TABLES=T BY Grade
/FORMAT=AVALUE TABLES
/CELLS=COUNT
/COUNT ROUND CELL.
    
```

Crosstabs

Notes

Output Created		22-DEC-2022 00:15:05
Comments		
Input	Active Dataset	DataSet1
	Filter	<none>
	Weight	<none>
	Split File	<none>
	N of Rows in Working Data File	784
Missing Value Handling	Definition of Missing	User-defined missing values are treated as missing.
	Cases Used	Statistics for each table are based on all the cases with valid data in the specified range(s) for all variables in each table.

Syntax		CROSSTABS /TABLES=T BY Grade /FORMAT=AVALUE TABLES /CELLS=COUNT /COUNT ROUND CELL.
Resources	Processor Time	00:00:00.01
	Elapsed Time	00:00:00.00
	Dimensions Requested	2
	Cells Available	524245

Case Processing Summary

	Valid		Cases Missing		Total	
	N	Percent	N	Percent	N	Percent
Ukuran Tumor * Grade	784	100.0%	0	0.0%	784	100.0%

Ukuran Tumor * Grade Crosstabulation

Count		Grade			Total
		Low	Moderate	High	
Ukuran Tumor	1	0	1	1	2
	2	17	26	4	47
	3a	22	95	0	117
	3b	2	21	27	50
	4a	9	36	11	56
	4b	17	155	50	222
	4c	23	184	83	290
Total		90	518	176	784